Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New Haven, Connecticut 06510


The investigators propose a placebo-controlled, randomized clinical trial that would enroll 50 postpartum women with a history of cocaine abuse or dependence to assess whether progesterone (100mgs twice daily) decreases postpartum cocaine use.

Study summary:

Specific Aim 1: To evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo. Hypothesis 1: Compared to women who are randomized to placebo, those assigned to progesterone will use less cocaine as measured by urine toxicology results and self-reported days of use. Specific aim 2: To obtain information about the safety and tolerability of progesterone treatment in the postpartum period. Hypothesis 2: Side effects for progesterone will be similar to those of placebo.


Inclusion Criteria: - Gravidas (women who delivered a baby in the past 12 weeks) who are 18 or older are eligible to participate. - Women must meet diagnostic criteria for abuse or dependence of cocaine in the six-months prior to conception or during pregnancy. - Women who abuse other illicit substances or alcohol would also be eligible as long as cocaine was their primary drug of abuse. If women are also opiate dependent, they must be undergoing treatment with methadone or buprenorphine. While we propose to target cocaine we will also monitor the ability of women with polysubstance use to maintain abstinence from substances other than cocaine. Exclusion Criteria: Women will be ineligible for the trial if they: 1. have a history of major medical illnesses including liver diseases, suspected or known malignancy, thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or bleeding disorders, heart disease, diabetes, history of stroke or other medical conditions that the physician investigator deems as contraindicated for participation in the study; 2. have a known allergy to progesterone or peanuts (vehicle for micronized progesterone); 3. speak a language other than English; 4. are planning on moving out of the area in the first six months after delivery; 5. are unable to understand the study or are unable to provide informed consent; 6. are currently undergoing treatment with another pharmacological agent for substance abuse treatment (with the exception of methadone or buprenorphine as above); 7. have pending incarceration; 8. are currently incarcerated; 9. are using another progestin; 10. are unwilling to accept randomization; 11. are unwilling to use a barrier method of birth control for the duration of the study to ensure that they will not become pregnant.



Primary Contact:

Principal Investigator
Kimberly A Yonkers, MD
Yale School of Medicine

Backup Contact:


Location Contact:

New Haven, Connecticut 06510
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.